Abstract
Selective serotonin reuptake inhibitors (SSRIs) are the first line pharmacological treatment of Major Depressive Disorder (MDD), but only about half of patients benefit from it. Cerebral serotonin 4 receptor (5-HT4R) binding measured with positron emission tomography (PET) is inversely related to serotonin levels and can serve as a proxy for brain serotonin levels. We here determine if 5-HT4R differs between healthy and MDD individuals and if it is associated with successful outcomes of serotonergic treatment of MDD. We [11C]-SB207145 PET-scanned 100 (71 F) untreated patients with moderate to severe MDD and 91 (55 F) healthy controls; 40 patients were re-scanned after 8 weeks treatment. All patients started treatment with the SSRI escitalopram and were followed clinically after 1, 2, 4, 8 and 12 weeks. Treatment response was measured as change from baseline.
Before treatment, patients with MDD had 8% lower global 5-HT4R binding than controls (95%CI[-13.1%;-2.5%], p<0.001). Non-responders did not differ from controls, whereas remitters had 9% lower binding than controls ([-16.1%;-2.7%], p=0.004). Independent of treatment outcomes, patients reduced their neostriatal 5-HT4R binding (−9%, [-12.8%;-5.0%], p<0.001) after serotonergic intervention.
Overall, patients with MDD have lower cerebral 5-HT4R binding than controls, suggesting that 5-HT4R is a biomarker for MDD. The observation that SSRI treatment leads to reduced neostriatal 5-HT4R binding supports that the treatment does indeed increase brain 5-HT levels. Patients who remit to SSRIs have lower cerebral 5-HT4R prior to treatment than controls whereas non-responders do not differ. We propose that non-responders to SSRI’s constitute a subgroup with non-serotonergic depression.
ClinicalTrials.gov Identifier: NCT02869035
Registry name: Treatment Outcome in Major Depressive Disorder
URL: https://clinicaltrials.gov/ct2/show/NCT02869035?term=NCT02869035&draw=2&rank=1
Competing Interest Statement
Prof. Knudsen has received honoraria as expert advisor for Sage Therapeutics and Sanos. Dr. Frokjaer has served as consultant for SAGE therapeutics. Prof. Jorgensen has given talks sponsored by Boehringer Ingelheim and H. Lundbeck. All other authors declare no conflict of interest.
Clinical Trial
NCT02869035
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/32792991/
Funding Statement
Economic support was granted from the Innovation Fund Denmark (GrantID: 5189-00087A), The Lundbeck Foundation alliance BrainDrugs (R279-2018-1145), Research Fund of the Mental Health Services - Capital Region of Denmark, Independent Research Fund Denmark (GrantID: DFF-6120-00038), G.J. Foundation, Research Council of Rigshospitalet, Augustinus Foundation (GrantID: 16-0058), Savvaerksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat, and the H. Lundbeck A/S. H. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent prior to inclusion and recruitment was performed by a trained study physician. The study protocol was approved by all relevant authorities (the Health Research Ethics Committee of the Capital Region of Denmark (H-15017713), the Danish Data Protection Agency (04711/RH-2016-163) and Danish Medicines Agency (EudraCT- 2016-001626-34)) and registered as a clinical trial before initiation (NCT02869035). The study was monitored by an external good clinical practice unit from the capital region of Copenhagen, Denmark.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared senior authorship
Data Availability
Data can be shared upon request and in compliance with GDPR regulations. www.nru.dk